Jonathan Roses counsels an array of clients, including life sciences companies focused on the areas of small molecule pharmaceuticals, pharmaceutical formulations, medical devices, and surgical methods. Jonathan is highly skilled in conducting and managing domestic and foreign patent prosecution and pre-litigation investigations, including worldwide freedom to operate, patentability, and exclusivity analyses. He is also experienced in representing clients in federal district court litigation and in post-grant proceedings before the United States Patent and Trademark Office and foreign counterparts. Jonathan has also provided regulatory advice and representation to clients relating to patent term extension and Orange Book listings under the Hatch-Waxman Act. He has a proven track record of building client relationships, teaching and mentoring junior attorneys and providing top-notch service and results.
Prior to joining Wolf Greenfield, Jonathan served as Counsel at Wilmer Hale, where he prosecuted and managed prosecution of patent applications worldwide for domestic and foreign life sciences, universities, and consumer clients in the chemical, pharmaceutical, biotechnology and materials science arts. He represented innovator pharmaceutical companies in ANDA (Hatch-Waxman) and 505(b)(2) patent infringement litigations involving Paragraph III and IV challenges of Orange Book listed patents covering several blockbuster drugs.
Before beginning his legal career, Jonathan was a medicinal chemist at Ariad Pharmaceuticals and Millennium Pharmaceuticals.